A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring schizophrenia, intramuscular injection, antipsychotic agents, dementia praecox, paliperidone palmitate, mental disorders, PANSS.
Eligibility Criteria
Inclusion Criteria: A DSM-IV diagnosis of schizophrenia (disorganized, catatonic, paranoid, residual, or undifferentiated type) for at least 1 year before the screening evaluation a total PANSS score of 70 to 120 at screening and baseline (pre-treatment) evaluations a body mass index (BMI [weight (kilograms)]/[height (meters)]²) of more than 17.0 kg/m² Exclusion Criteria: A primary active DSM-IV Axis I diagnosis other than schizophrenia a decrease of 25% or more in the total PANSS score between screening and baseline evaluations a DSM-IV diagnosis of active substance dependence within 3 months of screening evaluation a history of treatment resistance as defined by failure to respond to 2 adequate trials of different antipsychotic medications a woman who is pregnant, breast-feeding, or planning to become pregnant during the study period.